Abstract:Neutrophilic inflammation, which often persists over days despite appropriate antibiotic therapy, contributes substantially to brain damage in bacterial meningitis. We hypothesized that persistent inflammation is the consequence of a vicious cycle in which inflammation-induced cell injury leads to the release of endogenous danger molecules (e.g. high mobility group box 1) that drive the inflammatory response, causing further damage. The present study aimed to assess the mechanisms of high mobility group box 1 protein release and its functional relevance for the development and progression of pneumococcal meningitis. High mobility group box 1 was found in large quantities in cerebrospinal fluid samples of patients and mice with pneumococcal meningitis (predominantly in advanced stages of the disease). By using macrophages, we demonstrated that the release of high mobility group box 1 from macrophages following pneumococcal challenge is passive in nature and probably not connected with inflammasome- and oxidative stress-dependent inflammatory cell death forms. In a mouse meningitis model, treatment with the high mobility group box 1 antagonists ethyl pyruvate or Box A protein had no effect on the development of meningitis, but led to better resolution of inflammation during antibiotic therapy, which was accompanied by reduced brain pathology and better disease outcome. Additional experiments using gene-deficient mice and murine neutrophils provided evidence that high mobility group box 1 acts as a chemoattractant for neutrophils in a receptor for advanced glycosylation end products-dependent fashion. In conclusion, the present study implicated high mobility group box 1, likely released from dying cells, as a central propagator of inflammation in pneumococcal meningitis. Because persistent inflammation contributes to meningitis-associated brain damage, high mobility group box 1 may represent a promising target for adjunctive therapy of this disease.

The gesture life of high mobility group box 1

Relationship of high mobility group boxl and inflammation

Pathophysiological Function of HMGB1 As a Late- Acting Mediator of Inflammation

The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases

Novel Insights For High Mobility Group Box 1 Protein-Mediated Cellular Immune Response In Sepsis: A Systemic Review

Molecular Mechanism And Therapeutic Modulation Of High Mobility Group Box 1 Release And Action: An Updated Review

High mobility group box 1 in the central nervous system: regeneration hidden beneath inflammation

High Mobility Group Box 1 Protein As a Potential Drug Target for Infection- and Injury-Elicited Inflammation.

High Mobility Group Box 1 and Cardiovascular Diseases: Study of Act and Connect

[Advances in high mobility group box-1 protein mediated multiple organ dysfunction and its potential interventional strategies].

HMGB1 as a DNA-binding cytokine

Relationship Between High Mobility Group Box- 1 Protein and Inflammation

[The Potential Role of High Mobility Group Box 1 Protein in Immune Dysfunction and Its Regulatory Mechanism after Major Trauma].

Overview of the Role of High Mobility Group Box 1 Protein in Cardiovascular diseases

High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis

Interferon Regulatory Factor-1 Mediates the Release of High Mobility Group Box-1 in Endotoxemia in Mice

Inflammatory Response and Immune Regulation of High Mobility Group Box-1 Protein in Treatment of Sepsis.

High mobility group box1 protein is involved in acute inflammation induced by Clostridium difficile toxin A.

High Mobility Group Box 1 Inhibitors As Potential Therapeutic Agents in HMGB1-related Diseases

Advancement in Cytokine Effect of High Mobility Group Box 1 Protein

The Role of High Mobility Group Box 1 in Ischemic Stroke